AVE 25.0% 0.3¢ avecho biotechnology limited

Ann: TPM Cannabinoid Development Program Update, page-4

  1. 5,792 Posts.
    lightbulb Created with Sketch. 16423
    CBD absorption from formulations containing TPM was compared against a commonly prescribed CBD product comprising CBD at 100 mg/ml.

    All TPM formulations produced higher mean AUC and Cmax than the commercial CBD formulation.
    • Increases in AUC produced by TPM® formulations ranged from ~4-40 times
    • Increases in Cmax produced by TPM® formulations ranged from ~6-41 times
    • These increases were statistically significant for the best performing TPM® formulations

    The only commonly prescribed pure CBD product which is also FDA and EMA approved is GW Pharma’s Epidiolex (it also received TGA approval last month).

    Epidiolex is an oral solution at 100mg/mL. It incorporates sesame seed oil as a lipid solvent.

    Epidiolex was launched in the US just under two years ago. The company reported just under US$300 m in sales in its first year on the market.

    https://reference.medscape.com/drug/epidiolex-cannabidiol-1000225

    https://ir.gwpharm.com/news-release...-plc-reports-fourth-quarter-and-year-end-2019
 
watchlist Created with Sketch. Add AVE (ASX) to my watchlist
(20min delay)
Last
0.3¢
Change
-0.001(25.0%)
Mkt cap ! $9.508M
Open High Low Value Volume
0.3¢ 0.4¢ 0.3¢ $3.014K 954.7K

Buyers (Bids)

No. Vol. Price($)
39 98007692 0.3¢
 

Sellers (Offers)

Price($) Vol. No.
0.4¢ 29250202 14
View Market Depth
Last trade - 16.10pm 10/05/2024 (20 minute delay) ?
Last
0.3¢
  Change
-0.001 ( 25.0 %)
Open High Low Volume
0.3¢ 0.3¢ 0.3¢ 2078338
Last updated 15.59pm 10/05/2024 ?
AVE (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.